Iq-ai Share Discussion Threads

[festario] 24/10/2023 11:12

Price is 3.8p to sell 300k shares

[festario] 24/10/2023 11:04

Absolutely, and other late reports popping up to. A return to 4p and above, judging by the hidden demand.

[howdlep] 24/10/2023 11:03

nice to see a 564k buy

[festario] 24/10/2023 09:54

Interesting, I wasn't aware of that.

[howdlep] 24/10/2023 09:48

and of course there is the usual trick of trying to make people think there are two 75k sells, particularly with trading systems like advfn, that do not show a negative sign. So just to be clear the 75k at 3.5p was cancelled, leaving the 75k buy t 3.7p

[festario] 24/10/2023 09:31

3.75p the advertised mid price, but it's 3.8p to sell in size. So, it will go higher

[festario] 24/10/2023 08:28

As evidenced by the fact they I can now sell 600,000 shares at just above the bid!

[festario] 24/10/2023 08:18

Possible next leg up, as it bounces off the bottom of the ascending trend line.

[festario] 23/10/2023 14:29

Nowhere near enough visible sells to wipe 9% off the bid today. Not only that, but the bid gets dropped without any visible sells causing it, not even late reported. Which leads me to suspect that the real selling is happening off market.More FAB unloading I'd surmise.

[clocktower] 20/10/2023 14:08

It seems to have settled in this band now, which is a good sign.

[festario] 19/10/2023 09:03

The company have said as much, but it's a question of how the do that. A partnership with Bayer or GE could be good, but they would want a huge amount of equity. Trevor lending the money, but that could hurt us depending how low the options price would be. A placing, but that would mean dilution, and an admission that no partner was interested.

[rock star] 19/10/2023 08:42

It doesn’t take a rocket scientist to recognise they need cash.

[festario] 18/10/2023 14:14

I think the market needs to see an RNS that it understands, and likes. The next RNS needs to be guidance on increasing revenue and moving towards a cash flow positive situation within a year.

[bad gateway] 18/10/2023 14:10

Thanks fest appreciate the reply and the headsup on the RNS.
Can't force the market to buy can only have confidence in our own decisions and hold.
Liked the RNS myself, may not have screamed "buy" to the market but still confidence instilling in that their tech is undeniably useful to the medical profession. Just need a few sales RNS's to complement these technical ones at a guess.

[festario] 18/10/2023 13:50

In which case you'd be wrong BG. I re bought over 700k in the 3.85p area, but they are already in a losing position. Not helped by this latest positive sounding RNS just now, a result of which the market makers won't allow anyone to sell any shares. The market simply doesn't believe in Trevor's ability to create a viable, commercial business.

[bad gateway] 18/10/2023 13:31

Still assuming myself the seller is you Fest. How many did you sell last time the share price was over 4p?

[festario] 18/10/2023 13:19

Chart has officially broken down now I'm afraid.An RNS which is a Director sell, albeit in different words, will always do that. If the next RNS is a reduction by FAB, as I expect, then yes, we can expect the share price to be in the 2p range

[festario] 16/10/2023 10:59

Bid for 200k is up from 3.73p at open to 4.07p now.That's positive, but there is a seller at anything over 4p, which I assume is Trevor / FAB, so no real point in fighting against that with my spare funds at the moment.

[parsons4] 14/10/2023 07:54

Watching this one carefully !! but quite a lot of rubbish posted here. It looks to me like they need to raise funds unless I am missing something ?

[bad gateway] 13/10/2023 13:56

re the "Rare Pediatric Disease Priority Review Voucher"



GLOBAL GENES
RARE Daily

Mirum Sells Rare Pediatric Disease Priority Review Voucher
November 17, 2021



Mirum Pharmaceuticals said it has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher for $110 million to an undisclosed company.

The PRV was granted by the U.S. Food and Drug Administration in September 2021 with the approval of Livmarli (maralixibat) oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome one year of age and older.

Alagille syndrome (ALGS) is a rare genetic disorder in which bile ducts are abnormally narrow, malformed and reduced in number, which leads to bile accumulation in the liver and ultimately progressive liver disease. In patients with ALGS, multiple organ systems may be affected by the mutation, including the liver, heart, kidneys and central nervous system. The accumulation of bile acids prevents the liver from working properly to eliminate waste from the bloodstream and almost three quarters of patients with ALGS have a liver transplant before reaching adulthood. The pruritus experienced by patients with ALGS is among the most severe in any chronic liver disease and is present in most affected children by the third year of life.

The FDA grants Rare Pediatric Disease designation for serious or life-threatening diseases with manifestations in individuals aged from birth to 18 years, which includes access to the FDA’s expedited review and approval process and makes the developing company eligible for a Rare Pediatric Disease Priority Review voucher upon approval of the therapy by the FDA. The vouchers can be used to reduce the time of an FDA new drug approval review to six months from ten months. The vouchers are also potentially lucrative because they are transferable. Most recently, Albireo sold a priority review voucher for $105 million.

[festario] 13/10/2023 09:27

Probably Clocky. As it's NT to sell any shares at all with both my brokers.

[clocktower] 13/10/2023 08:49

Back towards 3p and value time again. :-)

[festario] 13/10/2023 08:35

Mr Market seems disappointed.

[bad gateway] 13/10/2023 08:03

Noteworthy quote imo.

"Once that submission is under review, and to leverage our ODD designation for pediatric brain tumors (GBM and ATRT), we will apply for a Rare Pediatric Disease Priority Review Voucher (RPD-PRV). Like the Fast Track program, RPD-PRV is another accelerated pathway authorised by the FDA which offers incentives for development and approval for promising drugs. If IB is successful in applying for an RPD-PRV, the vouchers can be transferred (sold) to other companies and the trading price of a PRV, per KIDS V CANCER (givekidsachanceact.org), is averaging $100 million"

Still going through the regulatory process by the sounds of things but big ambitions.

[clocktower] 13/10/2023 08:01

Positive letter today but very cautious now. It was a nice little spike.